The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
BACKGROUND: Despite the advances in the multidisciplinary treatment of gastric adenocarcinoma, the overall 5-year survival remains only 33.3% in North America. R0 resection with adequate lymphadenectomy remains the mainstay therapy…